Title:
CD123-TARGETTING ANTIBODIES AND USES THEREOF IN CANCER THERAPIES
Document Type and Number:
WIPO Patent Application WO/2023/020471
Kind Code:
A1
Abstract:
Provided herein are anti-CD123 antibodies and antigen-binding fragments thereof, chimeric antigen receptors (CARs) having the antibodies or the antigen-binding fragments (CD123 CARs), and genetically modified immune effector cells having such CARs. Polynucleotides encoding the antibodies, the antigen-binding fragments or the CARs are also provided. Compositions comprising the antibodies, the antigen-binding fragments or the CARs are also provided. The use of the antibodies, the antigen-binding fragments and the genetically modified immune effector cells having such CARs in cancer treatment are also provided.
Inventors:
ZHAO YANGBING (CN)
ZHU GENGZHEN (CN)
LIU XIAOJUN (CN)
ZHU GENGZHEN (CN)
LIU XIAOJUN (CN)
Application Number:
PCT/CN2022/112724
Publication Date:
February 23, 2023
Filing Date:
August 16, 2022
Export Citation:
Assignee:
UTC THERAPEUTICS SHANGHAI CO LTD (CN)
International Classes:
C07K16/30; A61K39/395; A61P35/02; C07K16/46; C12N5/078; C12N5/0783; C12N15/13; C12N15/62; C12N15/64; C12N15/85
Domestic Patent References:
WO2021016174A1 | 2021-01-28 | |||
WO2022037520A1 | 2022-02-24 | |||
WO2022036495A1 | 2022-02-24 |
Foreign References:
CN106103490A | 2016-11-09 | |||
CN107438618A | 2017-12-05 | |||
US20200165348A1 | 2020-05-28 |
Other References:
SARAH TETTAMANTI, ANDREA BIONDI, ETTORE BIAGI, DOMINIQUE BONNET: "CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics", ONCOIMMUNOLOGY, vol. 3, no. 5, 1 May 2014 (2014-05-01), pages e28835, XP055150827, DOI: 10.4161/onci.28835
Attorney, Agent or Firm:
SHANGHAI DIANSHI PARTNERS, P.C. (CN)
Download PDF:
Previous Patent: STORAGE MOTHERBOARD BASED ON FEITENG PROCESSOR
Next Patent: MESOTHELIN-TARGETTING ANTIBODIES AND USES THEREOF IN CANCER THERAPIES
Next Patent: MESOTHELIN-TARGETTING ANTIBODIES AND USES THEREOF IN CANCER THERAPIES